Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
'Weezer: The Gathering' 2026 tour: How to get tickets, prices, dates and more - 26 Eyewear Brands Worth Purchasing
- 3Transcript: NASA's Jared Isaacman on "Face the Nation with Margaret Brennan," April 5, 2026
- 4The Best 15 Applications for Efficiency and Association
- 5A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- How did life begin on Earth? New experiments support 'RNA world' hypothesis
- UN panel says Israel operating 'de facto policy of torture'
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China
- Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
